Delcath Systems (DCTH) Price & Analysis

Compare

770 Followers

DCTH Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.08 - $18.23

Previous CloseN/A

Volume96.76K

Average Volume (3M)702.42K

Market Cap

$388.29M

Enterprise Value$467.56M

Total Cash (Recent Filing)$81.00M

Total Debt (Recent Filing)$993.00K

Price to Earnings (P/E)256.0

Beta1.51

Next Earnings

Nov 11, 2025

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.07

Shares Outstanding34,981,255

10 Day Avg. Volume441,351

30 Day Avg. Volume702,416

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.20

Enterprise Value/Revenue6.82

Enterprise Value/Gross Profit7.75

Enterprise Value/Ebitda35.13

Forecast

1Y Price Target

$22.75

Price Target Upside95.28% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Adoption And ExpansionHEPZATO’s participation in the Medicaid National Drug Rebate Agreement (NDRA) program is expected to increase access and thus overall treatment volumes.

Market OpportunityDelcath estimates a combined $1.0B market opportunity for Hepzato in liver metastases due to colorectal and breast cancer, an attractive long-term growth opportunity.

Revenue And GrowthHepzato and Chemosat revenue beat consensus, signaling continued growth.

Bears Say

Pricing ImpactDelcath plans to participate in 340b program and introduce a ~23.1% discount on Hepzato sold to all 340b hospitals.

Revenue GuidanceManagement modestly lowered 2025 revenue guidance to $93M-$96M, from prior $94M-$98M.

Delcath Systems News

Delcath Systems doses first patient in Hepzato combination trial

Delcath Systems (DCTH) announced that the first patient has been dosed at the City of Hope National Medical...

19d ago

DCTH

Delcath Systems Updates Bylaws for Governance Efficiency

An update from Delcath Systems ( ($DCTH) ) is now available. On August 12, 2025, Delcath Systems, Inc....

22d ago

DCTH

Delcath Systems’ HEPZATO Drives Strong Growth and Expansion, Justifying Buy Rating

H.C. Wainwright analyst Swayampakula Ramakanth has maintained their bullish stance on DCTH stock, giving a Buy rating yesterday....

1M ago

DCTH

Delcath Systems price target raised to $31 from $29 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Delcath Systems (DCTH) to $31 from $29 and keeps a...

1M ago

DCTH

Delcath Systems Reports Strong Q2 2025 Results

Delcath Systems, Inc. ( ($DCTH) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

DCTH

Delcath Systems Reports Strong Q2 Growth Amid Challenges

Delcath Systems, Inc. (($DCTH)) has held its Q2 earnings call. Read on for the main highlights of the...

1M ago

DCTH

Delcath Systems price target raised to $27 from $26 at Clear Street

Clear Street raised the firm’s price target on Delcath Systems (DCTH) to $27 from $26 and keeps a...

1M ago

DCTH

Delcath Systems reports Q2 EPS 7c, consensus 3c

Reports Q2 revenue $24.16M, consensus $23.02M. “The consistent utilization of HEPZATO at treating sites and continued positive feedback...

1M ago

DCTH

DCTH Upcoming Earnings Report: What to Expect?

Delcath Systems, Inc. (DCTH) is scheduled to report 2nd quarter earnings on 08/06/2025, before the market opens. Regarding...

1M ago

DCTH

Strategic Growth Potential for Delcath Systems: Buy Rating Backed by CHOPIN Trial and Market Expansion

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on Delcath Systems (DCTH – Research Report)....

2M ago

DCTH

Delcath Systems management to meet virtually with Stephens

Virtual Meeting to be held on June 17-18 hosted by Stephens. Published first on TheFly – the ultimate...

3M ago

DCTH

Delcath Systems: Promising Growth Prospects and Strategic Initiatives Justify Buy Rating

In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Delcath Systems (DCTH...

3M ago

DCTH

Delcath Systems price target raised to $29 from $24 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Delcath Systems (DCTH) to $29 from $24 and keeps a...

4M ago

DCTH

Delcath Systems Announces 2025 Financial Guidance

The latest update is out from Delcath Systems ( ($DCTH) ). On May 22, 2025, Delcath Systems announced...

4M ago

DCTH

DCTH FAQ

What was Delcath Systems’s price range in the past 12 months?

Delcath Systems lowest stock price was $8.08 and its highest was $18.23 in the past 12 months.

What is Delcath Systems’s market cap?

Delcath Systems’s market cap is $388.29M.

When is Delcath Systems’s upcoming earnings report date?

Delcath Systems’s upcoming earnings report date is Nov 11, 2025 which is in 65 days.

How were Delcath Systems’s earnings last quarter?

Delcath Systems released its earnings results on Aug 06, 2025. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.027 by $0.043.

Is Delcath Systems overvalued?

According to Wall Street analysts Delcath Systems’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Delcath Systems pay dividends?

Delcath Systems does not currently pay dividends.

What is Delcath Systems’s EPS estimate?

Delcath Systems’s EPS estimate is -0.04.

How many shares outstanding does Delcath Systems have?

Delcath Systems has 34,981,255 shares outstanding.

What happened to Delcath Systems’s price movement after its last earnings report?

Delcath Systems reported an EPS of $0.07 in its last earnings report, beating expectations of $0.027. Following the earnings report the stock price went up 1.141%.

Which hedge fund is a major shareholder of Delcath Systems?

Currently, no hedge funds are holding shares in DCTH

Delcath Systems Stock Smart Score

Underperform

Fundamentals

Return on Equity

4.09%

Trailing 12-Months

Asset Growth

244.63%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Delcath Systems

Delcath Systems, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of cancer. The company primarily operates in the oncology sector, specializing in its proprietary Chemosaturation Technology System (CTS), which is designed to deliver high-dose chemotherapy directly to tumors while minimizing systemic exposure. Delcath's core product offerings include the CTS for the treatment of liver cancers, particularly in patients with metastatic melanoma and other tumors that have spread to the liver.

Delcath Systems (DCTH) Earnings & Revenues

Historic Earnings Reports

DCTH Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted the company's strong revenue growth and positive financial performance, along with strategic expansions and future trial prospects. However, the call also noted challenges in site activations, revenue guidance adjustments, and increased R&D expenses. The participation in the 340B program presents both opportunities and challenges.View all DCTH earnings summaries

DCTH Stock 12 Month Forecast

Average Price Target

$22.75

▲(95.28% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","19":"$19","32":"$32","12.5":"$12.5","25.5":"$25.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,12.5,19,25.5,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.59,12.16,13.73,15.3,16.87,18.44,20.009999999999998,21.58,23.15,24.72,26.29,27.86,29.43,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.59,11.525384615384615,12.46076923076923,13.396153846153846,14.331538461538461,15.266923076923078,16.20230769230769,17.13769230769231,18.073076923076922,19.00846153846154,19.943846153846152,20.87923076923077,21.814615384615387,{"y":22.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.59,10.698461538461538,10.806923076923077,10.915384615384616,11.023846153846154,11.132307692307693,11.240769230769232,11.349230769230768,11.457692307692307,11.566153846153846,11.674615384615384,11.783076923076923,11.891538461538461,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.05,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.19,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.86,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.17,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.57,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.76,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >